TriNet Group, Inc. Q3 FY2026 earnings call

• Strategic Priorities: Management confirmed progress on three key goals: completing health fee repricing (ICR within target range), improving retention through technology/service enhancements, and driving new sales growth via an expanded sales force and broker channel.
• Customer Retention & Technology: Retention has recovered from Q1 repricing impacts. AI tool 'Trinet Assistant' now resolves nearly 60% of WSE chats, reducing backlog by 60% and leave-of-absence turnaround times by 75%. Record Net Promoter Scores observed.
• Ecosystem Expansion: Launched Trinet Global, Trinet IT, Trinet Recruit, and Trinet Spend. Acquired Cocoon to strengthen leave-of-absence workflows. These integrations aim to deepen client stickiness and support both retention and new sales.
• Sales Momentum: New sales ACV grew mid-single digits in Q3, with forecasts pointing to high single-digit growth in Q4. The Ascend program is building a pipeline of productive sales consultants, and the broker channel is becoming a significant contributor.
• Insurance Performance: ICR came in at 89%, a 1-point improvement YoY. Pharma costs were below forecast but medical costs benefited from lower inpatient procedures. Health cost trends remain in the high single digits.
• Financial Discipline: Operating expenses increased 2% YoY due to strategic investments and Cocoon integration. Effective tax rate dropped to 19% due to R&D credits. Strong cash generation ($80M operating cash flow) supports share repurchases and dividends.

• Total Revenue: $1.2 billion (down 5% YoY). WSE count ended at ~295,000 (down 11% YoY).
• Professional Services Revenue: $157 million (down 7% YoY), trending toward the high end of full-year guidance.
• Insurance Services Revenue: Declined 4% YoY due to lower WSE volumes, offset by pricing increases.
• Interest Revenue: $13 million (down 24% YoY) due to reduced cash balances for tax credits.
• Adjusted EBITDA: $89 million with a margin of 7.6%. Full-year margin is trending toward the high end of the 8.5%-9.0% range.

• Total Revenues: Range unchanged at $4.75–$4.9 billion; trending toward the bottom end due to Q1 repricing headwinds.
• Professional Services Revenue: Range unchanged at $647–$663 million; trending toward the high end.
• Insurance Cost Ratio (ICR): Range unchanged at 88.5%–89.5%; tracking toward the low end (88.5%) despite seasonal Q4 increases.
• Adjusted EBITDA Margin: Range unchanged at 8.5%–9.0%; trending toward the high end.
• EPS Guidance: GAAP EPS range $2.85–$3.35; Adjusted EPS range $4.50–$5.10. Management signaled adjusted EPS will hit the high end ($5.10) driven by Q3 outperformance and favorable ICR trends.

• Healthcare Cost Trends: Persistent high single-digit healthcare inflation poses ongoing pressure on margins. While pharma costs are currently below forecast, management warns that future introduction of high-cost drugs (e.g., GLPs) may normalize or increase trends.
• Seasonal Volatility: Q4 typically sees higher insurance costs due to deductible resets and year-end claims volatility, which could impact ICR.
• Retention Sensitivity: Early-year retention was negatively impacted by health fee repricing; continued price alignment with market trends is critical to maintaining recovery.
• Macroeconomic Headwinds: Mixed economic conditions and rising interest rates have slowed SMB net hiring, impacting professional services volume.

Q: Jared Levin asked about the sustainability of recent sales acceleration and the impact of adding sales headcount in early 2027. / A: CEO Mike Simonds highlighted encouraging momentum, forecasting high-single-digit new sales ACV growth in Q4. He attributed this to the 'Ascend' program boosting consultant capacity by over 10% and strong performance in the broker channel. Simonds emphasized that these investments create a sustainable foundation for repeatable growth rather than just temporary headcount increases, with significant runway remaining in the broker network.

Q: Analysts queried the implied ICR degradation in Q4 guidance and the sustainability of current insurance cost improvements. / A: CFO Mala Murthy explained that Q4 historically carries the highest ICR due to deductible resets and burned-out pools, not operational weakness. She noted that YTD outperformance makes the Q4 trend appear worse by comparison. Both executives stressed that while pharma costs are currently favorable, long-term trends remain high single-digit, and pricing is targeting the top end of the 87-90% ICR range to manage sustained healthcare inflation.

Q: Ross Cole asked about drivers behind the potential step-down in EPS for Q4 relative to expectations. / A: Murthy clarified that full-year adjusted EPS is tracking to the high end of guidance ($5.10) due to two factors: Q3 outperformance against internal expectations (driven by interest income and ICR beats) and continued favorable ICR trends. She indicated that reinvesting some Q3 beat into strategic investments explains the variance, but the overall trajectory remains strong at the top of the range.

Q: David Grossman asked how the company’s risk-taking model compares to pass-through competitors as healthcare costs remain elevated. / A: Simonds stated that taking risk allows Trinet to reprice cohorts quarterly, offering agility that annual-repricing competitors lack. While he expects structural growth rates to balance out at scale, this flexibility enables Trinet to capture outsized renewals and adjust pricing faster as trends moderate. He also noted minor downward pressure on health plan participation due to costs, leading to some 'buy-down' activity in plan designs.